Alexandre Barbosa Reis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1496467/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Immunochemotherapy for visceral leishmaniasis: combinatorial action of Miltefosine plus LBSapMPL vaccine improves adaptative Th1 immune response with control of splenic parasitism in experimental hamster model. Parasitology, 2022, 149, 371-379.	1.5	4
2	Comparative evaluation of meglumine antimoniate encapsulated in a mixture of conventional and PEGylated liposomes and immunotherapy using an anti-canine IL-10 receptor-blocking monoclonal antibody on canine visceral leishmaniasis. Molecular Immunology, 2022, 141, 70-78.	2.2	3
3	Successive Pandemic Waves with Different Virulent Strains and the Effects of Vaccination for SARS-CoV-2. Vaccines, 2022, 10, 343.	4.4	4
4	Down regulation of IL-10 and TGF-β1 mRNA expression associated with reduced inflammatory process correlates with control of parasitism in the liver after treatingL. infantuminfected dogs with the LBMPL vaccine therapy. Cytokine, 2022, 153, 155838.	3.2	1
5	From Spanish Flu to Syndemic COVID-19: long-standing sanitarian vulnerability of Manaus, warnings from the Brazilian rainforest gateway. Anais Da Academia Brasileira De Ciencias, 2021, 93, e20210431.	0.8	7
6	Establishment of monoclonal antibodies to evaluate the cellular immunity in a hamster model of <i>L infantum</i> infection. Parasite Immunology, 2021, 43, e12823.	1.5	4
7	A chimeric vaccine combined with adjuvant system induces immunogenicity and protection against visceral leishmaniasis in BALB/c mice. Vaccine, 2021, 39, 2755-2763.	3.8	11
8	Repositioning of Tamoxifen in Surface-Modified Nanocapsules as a Promising Oral Treatment for Visceral Leishmaniasis. Pharmaceutics, 2021, 13, 1061.	4.5	3
9	Genomic evidence of SARS-CoV-2 reinfection case with the emerging B.1.2 variant in Brazil. Journal of Infection, 2021, 83, 237-279.	3.3	12
10	IL-10 receptor blockade controls the in vitro infectivity of Leishmania infantum and promotes a Th1 activation in PBMC of dogs with visceral leishmaniasis. Molecular Immunology, 2021, 137, 20-27.	2.2	6
11	Logistics Workers Are a Key Factor for SARS-CoV-2 Spread in Brazilian Small Towns: Case-Control Study. JMIR Public Health and Surveillance, 2021, 7, e30406.	2.6	6
12	Heterologous vaccine therapy associated with half course of Miltefosine promote activation of the proinflammatory response with control of splenic parasitism in a hamster model of visceral leishmaniasis. Current Research in Immunology, 2021, 2, 194-201.	2.8	2
13	Phase I and II Clinical Trial Comparing the LBSap, Leishmune®, and Leish-Tec® Vaccines against Canine Visceral Leishmaniasis. Vaccines, 2020, 8, 690.	4.4	7
14	Liver infusion tryptose (LIT): the best choice for growth, viability, and infectivity of Leishmania infantum parasites. Parasitology Research, 2020, 119, 4185-4195.	1.6	5
15	Recent advances and new strategies on leishmaniasis treatment. Applied Microbiology and Biotechnology, 2020, 104, 8965-8977.	3.6	107
16	In vitro Infectivity of Strains Isolated From Dogs Naturally Infected With Leishmania infantum Present a Distinct Pathogenic Profile in Hamsters. Frontiers in Medicine, 2020, 7, 496.	2.6	1
17	Recent advances and new strategies in Leishmaniasis diagnosis. Applied Microbiology and Biotechnology, 2020, 104, 8105-8116.	3.6	22
18	Kinetics of Phenotypic and Functional Changes in Mouse Models of Sponge Implants: Rational Selection to Optimize Protocols for Specific Biomolecules Screening Purposes. Frontiers in Bioengineering and Biotechnology, 2020, 8, 538203.	4.1	0

#	Article	IF	CITATIONS
19	Impedimetric immunosensor for rapid and simultaneous detection of chagas and visceral leishmaniasis for point of care diagnosis. Biosensors and Bioelectronics, 2020, 169, 112573.	10.1	24
20	Chimeric Vaccines Designed by Immunoinformatics-Activated Polyfunctional and Memory T Cells That Trigger Protection against Experimental Visceral Leishmaniasis. Vaccines, 2020, 8, 252.	4.4	21
21	Laboratorial algorithm for serological diagnosis of visceral leishmaniasis using rK39-ICT, DAT-LPC and FC-Simplex IgG1. Journal of Immunological Methods, 2020, 480, 112765.	1.4	2
22	Worldwide COVID-19 spreading explained: traveling numbers as a primary driver for the pandemic. Anais Da Academia Brasileira De Ciencias, 2020, 92, e20201139.	0.8	18
23	Severe airport sanitarian control could slow down the spreading of COVID-19 pandemics in Brazil. PeerJ, 2020, 8, e9446.	2.0	28
24	Multiplex flow cytometry serology to diagnosis of canine visceral leishmaniasis. Applied Microbiology and Biotechnology, 2019, 103, 8179-8190.	3.6	6
25	Performance of recombinant chimeric proteins in the serological diagnosis of Trypanosoma cruzi infection in dogs. PLoS Neglected Tropical Diseases, 2019, 13, e0007545.	3.0	16
26	Synthetic Peptides Elicit Strong Cellular Immunity in Visceral Leishmaniasis Natural Reservoir and Contribute to Long-Lasting Polyfunctional T-Cells in BALB/c Mice. Vaccines, 2019, 7, 162.	4.4	15
27	Effect on cellular recruitment and the innate immune response by combining saponin, monophosphoryl lipid-A and Incomplete Freund's Adjuvant with Leishmania (Viannia) braziliensis antigens for a vaccine formulation. Vaccine, 2019, 37, 7269-7279.	3.8	5
28	Canine visceral leishmaniasis biomarkers and their employment in vaccines. Veterinary Parasitology, 2019, 271, 87-97.	1.8	27
29	Leishmania infantum nucleoside triphosphate diphosphohydrolase 1 (NTPDase 1) B-domain: Antibody antiproliferative effect on the promastigotes and IgG subclass responses in canine visceral leishmaniasis. Veterinary Parasitology, 2019, 271, 38-44.	1.8	2
30	Neutrophil properties in healthy and Leishmania infantum-naturally infected dogs. Scientific Reports, 2019, 9, 6247.	3.3	17
31	Label-free electrochemical impedance immunosensor based on modified screen-printed gold electrodes for the diagnosis of canine visceral leishmaniasis. Talanta, 2019, 195, 327-332.	5.5	42
32	Risk profile for Leishmania infection in dogs coming from an area of visceral leishmaniasis reemergence. Preventive Veterinary Medicine, 2018, 150, 1-7.	1.9	21
33	Effectiveness of deltamethrin-impregnated dog collars on the incidence of canine infection by Leishmania infantum: A large scale intervention study in an endemic area in Brazil. PLoS ONE, 2018, 13, e0208613.	2.5	23
34	Peptide Vaccines for Leishmaniasis. Frontiers in Immunology, 2018, 9, 1043.	4.8	59
35	Comparative analysis of real-time PCR assays in the detection of canine visceral leishmaniasis. Parasitology Research, 2018, 117, 3341-3346.	1.6	6
36	Comparative genomics of canine-isolated Leishmania (Leishmania) amazonensis from an endemic focus of visceral leishmaniasis in Governador Valadares, southeastern Brazil. Scientific Reports, 2017, 7, 40804.	3.3	65

#	Article	IF	CITATIONS
37	Impact of dose and surface features on plasmatic and liver concentrations of biodegradable polymeric nanocapsules. European Journal of Pharmaceutical Sciences, 2017, 105, 19-32.	4.0	13
38	Tcl, Tcll and TcVI Trypanosoma cruzi samples from Chagas disease patients with distinct clinical forms and critical analysis of in vitro and in vivo behavior, response to treatment and infection evolution in murine model. Acta Tropica, 2017, 167, 108-120.	2.0	33
39	Mixed Formulation of Conventional and Pegylated Meglumine Antimoniate-Containing Liposomes Reduces Inflammatory Process and Parasite Burden in Leishmania infantum-Infected BALB/c Mice. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	17
40	Association between mast cells, tissue remodelation and parasite burden in the skin of dogs with visceral leishmaniasis. Veterinary Parasitology, 2017, 243, 260-266.	1.8	5
41	Canine visceral leishmaniasis follow-up: a new anti-IgG serological test more sensitive than ITS-1 conventional PCR. Veterinary Parasitology, 2017, 248, 62-67.	1.8	8
42	Immunoinformatics Features Linked to Leishmania Vaccine Development: Data Integration of Experimental and In Silico Studies. International Journal of Molecular Sciences, 2017, 18, 371.	4.1	22
43	A Vaccine Therapy for Canine Visceral Leishmaniasis Promoted Significant Improvement of Clinical and Immune Status with Reduction in Parasite Burden. Frontiers in Immunology, 2017, 8, 217.	4.8	37
44	Impact of LbSapSal Vaccine in Canine Immunological and Parasitological Features before and after Leishmania chagasi-Challenge. PLoS ONE, 2016, 11, e0161169.	2.5	9
45	Multicomponent LBSap vaccine displays immunological and parasitological profiles similar to those of Leish-Tec® and Leishmune® vaccines against visceral leishmaniasis. Parasites and Vectors, 2016, 9, 472.	2.5	17
46	Clinical, hematological and biochemical alterations in hamster (Mesocricetus auratus) experimentally infected with Leishmania infantum through different routes of inoculation. Parasites and Vectors, 2016, 9, 181.	2.5	38
47	Host-Parasite Interactions in Chagas Disease: Genetically Unidentical Isolates of a Single Trypanosoma cruzi Strain Identified In Vitro via LSSP-PCR. PLoS ONE, 2015, 10, e0137788.	2.5	3
48	Genetic homogeneity among Leishmania (Leishmania) infantum isolates from dog and human samples in Belo Horizonte Metropolitan Area (BHMA), Minas Gerais, Brazil. Parasites and Vectors, 2015, 8, 226.	2.5	7
49	Multi-antigen print immunoassay (MAPIA)-based evaluation of novel recombinant Leishmania infantum antigens for the serodiagnosis of canine visceral leishmaniasis. Parasites and Vectors, 2015, 8, 45.	2.5	13
50	Setting the proportion of CD4+ and CD8+ T-cells co-cultured with canine macrophages infected with Leishmania chagasi. Veterinary Parasitology, 2015, 211, 124-132.	1.8	7
51	Novel Recombinant Multiepitope Proteins for the Diagnosis of Asymptomatic Leishmania infantum-Infected Dogs. PLoS Neglected Tropical Diseases, 2015, 9, e3429.	3.0	57
52	The Tcl and Tcll Trypanosoma cruzi experimental infections induce distinct immune responses and cardiac fibrosis in dogs. Memorias Do Instituto Oswaldo Cruz, 2014, 109, 1005-1013.	1.6	28
53	Prognostic Factors and Scoring System for Death from Visceral Leishmaniasis: An Historical Cohort Study in Brazil. PLoS Neglected Tropical Diseases, 2014, 8, e3374.	3.0	50
54	Immunotherapy and Immunochemotherapy in Visceral Leishmaniasis: Promising Treatments for this Neglected Disease. Frontiers in Immunology, 2014, 5, 272.	4.8	73

#	Article	IF	CITATIONS
55	Evaluation of Change in Canine Diagnosis Protocol Adopted by the Visceral Leishmaniasis Control Program in Brazil and a New Proposal for Diagnosis. PLoS ONE, 2014, 9, e91009.	2.5	59
56	Targeted Immunology for Prevention and Cure of VL. Frontiers in Immunology, 2014, 5, 660.	4.8	5
57	Dogs infected with the blood trypomastigote form of Trypanosoma cruzi display an increase expression of cytokines and chemokines plus an intense cardiac parasitism during acute infection. Molecular Immunology, 2014, 58, 92-97.	2.2	16
58	Immunological profile of resistance and susceptibility in naturally infected dogs by Leishmania infantum. Veterinary Parasitology, 2014, 205, 472-482.	1.8	43
59	Shotgun proteomics to unravel the complexity of the Leishmania infantum exoproteome and the relative abundance of its constituents. Molecular and Biochemical Parasitology, 2014, 195, 43-53.	1.1	19
60	A multicentric evaluation of the recombinant Leishmania infantum antigen-based immunochromatographic assay for the serodiagnosis of canine visceral leishmaniasis. Parasites and Vectors, 2014, 7, 136.	2.5	15
61	LBSapSal-vaccinated dogs exhibit increased circulating T-lymphocyte subsets (CD4+ and CD8+) as well as a reduction of parasitism after challenge with Leishmania infantum plus salivary gland of Lutzomyia longipalpis. Parasites and Vectors, 2014, 7, 61.	2.5	21
62	Cellular immunophenotypic profile in the splenic compartment during canine visceral leishmaniasis. Veterinary Immunology and Immunopathology, 2014, 157, 190-196.	1.2	12
63	Molecular diagnosis of canine visceral leishmaniasis: A comparative study of three methods using skin and spleen from dogs with natural Leishmania infantum infection. Veterinary Parasitology, 2013, 197, 498-503.	1.8	47
64	Canine visceral leishmaniasis: Incidence and risk factors for infection in a cohort study in Brazil. Veterinary Parasitology, 2013, 197, 411-417.	1.8	27
65	Dogs immunized with LBSap vaccine displayed high levels of IL-12 and IL-10 cytokines and CCL4, CCL5 and CXCL8 chemokines in the dermis. Molecular Immunology, 2013, 56, 540-548.	2.2	12
66	Analysis using canine peripheral blood for establishing in vitro conditions for monocyte differentiation into macrophages for Leishmania chagasi infection and T-cell subset purification. Veterinary Parasitology, 2013, 198, 62-71.	1.8	17
67	Cytokine and nitric oxide patterns in dogs immunized with LBSap vaccine, before and after experimental challenge with Leishmania chagasi plus saliva of Lutzomyia longipalpis. Veterinary Parasitology, 2013, 198, 371-381.	1.8	21
68	Development of a label-free immunosensor based on surface plasmon resonance technique for the detection of anti-Leishmania infantum antibodies in canine serum. Biosensors and Bioelectronics, 2013, 46, 22-29.	10.1	58
69	Effect of the preservative and temperature conditions on the stability of Leishmania infantum promastigotes antigens applied in a flow cytometry diagnostic method for canine visceral leishmaniasis. Diagnostic Microbiology and Infectious Disease, 2013, 76, 470-476.	1.8	7
70	An antigenic domain within a catalytically active Leishmania infantum nucleoside triphosphate diphosphohydrolase (NTPDase 1) is a target of inhibitory antibodies. Parasitology International, 2013, 62, 44-52.	1.3	15
71	Development of a Fluorescent Based Immunosensor for the Serodiagnosis of Canine Leishmaniasis Combining Immunomagnetic Separation and Flow Cytometry. PLoS Neglected Tropical Diseases, 2013, 7, e2371.	3.0	16
72	Evaluation of a Prototype Flow Cytometry Test for Serodiagnosis of Canine Visceral Leishmaniasis. Vaccine Journal, 2013, 20, 1792-1798.	3.1	12

#	Article	IF	CITATIONS
73	Clinical Forms of Canine Visceral Leishmaniasis in Naturally Leishmania infantum–Infected Dogs and Related Myelogram and Hemogram Changes. PLoS ONE, 2013, 8, e82947.	2.5	46
74	Risk Factors for Seroconversion by Leishmania infantum in a Cohort of Dogs from an Endemic Area of Brazil. PLoS ONE, 2013, 8, e71833.	2.5	34
75	Higher Expression of CCL2, CCL4, CCL5, CCL21, and CXCL8 Chemokines in the Skin Associated with Parasite Density in Canine Visceral Leishmaniasis. PLoS Neglected Tropical Diseases, 2012, 6, e1566.	3.0	39
76	An assessment on epitope prediction methods for protozoa genomes. BMC Bioinformatics, 2012, 13, 309.	2.6	24
77	Profile of anti-Leishmania antibodies related to clinical picture in canine visceral leishmaniasis. Research in Veterinary Science, 2012, 93, 705-709.	1.9	25
78	Different Infective Forms Trigger Distinct Immune Response in Experimental Chagas Disease. PLoS ONE, 2012, 7, e32912.	2.5	16
79	Cell Recruitment and Cytokines in Skin Mice Sensitized with the Vaccine Adjuvants: Saponin, Incomplete Freund's Adjuvant, and Monophosphoryl Lipid A. PLoS ONE, 2012, 7, e40745.	2.5	51
80	Parasite Burden in Hamsters Infected with Two Different Strains of Leishmania (Leishmania) infantum: "Leishman Donovan Units―versus Real-Time PCR. PLoS ONE, 2012, 7, e47907.	2.5	57
81	Performance of LBSap Vaccine after Intradermal Challenge with L. infantum and Saliva of Lu. longipalpis: Immunogenicity and Parasitological Evaluation. PLoS ONE, 2012, 7, e49780.	2.5	41
82	First description of autochthonous canine visceral leishmaniasis in the metropolitan region of Vitória, State of EspÃrito Santo, Brazil. Revista Da Sociedade Brasileira De Medicina Tropical, 2012, 45, 754-756.	0.9	6
83	Immunological changes in canine peripheral blood leukocytes triggered by immunization with first or second generation vaccines against canine visceral leishmaniasis. Veterinary Immunology and Immunopathology, 2011, 141, 64-75.	1.2	23
84	Qualitative and quantitative immunohistochemical evaluation of iNOS expression in the spleen of dogs naturally infected with Leishmania chagasi. Parasitology Research, 2011, 108, 1397-1403.	1.6	16
85	Cytokine and transcription factor profiles in the skin of dogs naturally infected by Leishmania (Leishmania) chagasi presenting distinct cutaneous parasite density and clinical status. Veterinary Parasitology, 2011, 177, 39-49.	1.8	46
86	Prevalence and Factors Associated with Leishmania infantum Infection of Dogs from an Urban Area of Brazil as Identified by Molecular Methods. PLoS Neglected Tropical Diseases, 2011, 5, e1291.	3.0	118
87	Influence of Clinical Status and Parasite Load on Erythropoiesis and Leucopoiesis in Dogs Naturally Infected with Leishmania (Leishmania) chagasi. PLoS ONE, 2011, 6, e18873.	2.5	32
88	Immunity to Leishmania and the rational search for vaccines against canine leishmaniasis. Trends in Parasitology, 2010, 26, 341-349.	3.3	101
89	Relationship of Leishmania-specific IgG levels and IgG avidity with parasite density and clinical signs in canine leishmaniasis. Veterinary Parasitology, 2010, 169, 248-257.	1.8	36
90	Leishmania (Viannia) braziliensis: Immunoblotting analysis for the detection of IgG subclasses in the diagnosis of symptomatic and asymptomatic dogs. Veterinary Parasitology, 2010, 173, 143-146.	1.8	2

#	Article	IF	CITATIONS
91	Trypanosoma cruzi: Serum levels of nitric oxide and expression of inducible nitric oxide synthase in myocardium and spleen of dogs in the acute stage of infection with metacyclic or blood trypomastigotes. Experimental Parasitology, 2009, 121, 76-82.	1.2	11
92	T-cell-derived cytokines, nitric oxide production by peripheral blood monocytes and seric anti-Leishmania (Leishmania) chagasi IgG subclass patterns following immunization against canine visceral leishmaniasis using Leishvaccine and Leishmune®. Vaccine, 2009, 27, 1008-1017.	3.8	34
93	Systemic and compartmentalized immune response in canine visceral leishmaniasis. Veterinary Immunology and Immunopathology, 2009, 128, 87-95.	1.2	156
94	Advances in flow cytometric serology for canine visceral leishmaniasis: Diagnostic applications when distinct clinical forms, vaccination and other canine pathogens become a challenge. Veterinary Immunology and Immunopathology, 2009, 128, 79-86.	1.2	18
95	Histological study of cell migration in the dermis of hamsters after immunisation with two different vaccines against visceral leishmaniasis. Veterinary Immunology and Immunopathology, 2009, 128, 418-424.	1.2	11
96	Canine visceral leishmaniasis: Performance of a rapid diagnostic test (Kalazar Detectâ,,¢) in dogs with and without signs of the disease. Acta Tropica, 2008, 107, 205-207.	2.0	37
97	Histopathological and immunohistochemical investigations of the hepatic compartment associated with parasitism and serum biochemical changes in canine visceral leishmaniasis. Research in Veterinary Science, 2008, 84, 269-277.	1.9	61
98	Antigenicity of a whole parasite vaccine as promising candidate against canine leishmaniasis. Research in Veterinary Science, 2008, 85, 106-112.	1.9	36
99	A killed Leishmania vaccine with sand fly saliva extract and saponin adjuvant displays immunogenicity in dogs. Vaccine, 2008, 26, 623-638.	3.8	48
100	Despite Leishvaccine and Leishmune® trigger distinct immune profiles, their ability to activate phagocytes and CD8+ T-cells support their high-quality immunogenic potential against canine visceral leishmaniasis. Vaccine, 2008, 26, 2211-2224.	3.8	31
101	Kinetics of cell migration to the dermis and hypodermis in dogs vaccinated with antigenic compounds of Leishmania braziliensis plus saponin. Vaccine, 2008, 26, 3922-3931.	3.8	12
102	Histopathology, parasite density and cell phenotypes of the popliteal lymph node in canine visceral leishmaniasis. Veterinary Immunology and Immunopathology, 2008, 121, 23-33.	1.2	58
103	Autochthonous canine visceral leishmaniasis in a non-endemic area: Bom Sucesso, Minas Gerais State, Brazil. Cadernos De Saude Publica, 2008, 24, 281-286.	1.0	8
104	Immunogenicity of a killed Leishmania vaccine with saponin adjuvant in dogs. Vaccine, 2007, 25, 7674-7686.	3.8	69
105	Clinical value of anti-Leishmania (Leishmania) chagasi IgG titers detected by flow cytometry to distinguish infected from vaccinated dogs. Veterinary Immunology and Immunopathology, 2007, 116, 85-97.	1.2	30
106	Differential impact of metacyclic and blood trypomastigotes on parasitological, serological and phenotypic features triggered during acute Trypanosoma cruzi infection in dogs. Acta Tropica, 2007, 101, 120-129.	2.0	20
107	Comparison of serological assays for the diagnosis of canine visceral leishmaniasis in animals presenting different clinical manifestations. Veterinary Parasitology, 2007, 146, 235-241.	1.8	104
108	Serological screening confirms the re-emergence of canine leishmaniosis in urban and rural areas in Governador Valadares, Vale do Rio Doce, Minas Gerais, Brazil. Parasitology Research, 2007, 100, 233-239.	1.6	20

#	Article	IF	CITATIONS
109	Parasite density and impaired biochemical/hematological status are associated with severe clinical aspects of canine visceral leishmaniasis. Research in Veterinary Science, 2006, 81, 68-75.	1.9	159
110	lsotype patterns of immunoglobulins: Hallmarks for clinical status and tissue parasite density in brazilian dogs naturally infected by Leishmania (Leishmania) chagasi. Veterinary Immunology and Immunopathology, 2006, 112, 102-116.	1.2	141
111	Use of PCR–RFLP to identify Leishmania species in naturally-infected dogs. Veterinary Parasitology, 2006, 140, 231-238.	1.8	70
112	Antibodies from dogs with canine visceral leishmaniasis recognise two proteins from the saliva of Lutzomyia longipalpis. Parasitology Research, 2006, 100, 449-454.	1.6	30
113	Establishment of a microplate assay for flow cytometric assessment and it is use for the evaluation of age-related phenotypic changes in canine whole blood leukocytes. Veterinary Immunology and Immunopathology, 2005, 103, 173-185.	1.2	39
114	Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis. Veterinary Research, 2005, 36, 827-838.	3.0	67
115	Evaluation of enzyme-linked immunosorbent assay using crude Leishmania and recombinant antigens as a diagnostic marker for canine visceral leishmaniasis. Memorias Do Instituto Oswaldo Cruz, 2005, 100, 197-203.	1.6	67
116	Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine. Vaccine, 2004, 22, 2234-2243.	3.8	121
117	A randomized double-blind placebo-controlled trial to evaluate the immunogenicity of a candidate vaccine against American tegumentary leishmaniasis. Acta Tropica, 2001, 80, 251-260.	2.0	35
118	Phase I and II open clinical trials of a vaccine against Leishmania chagasi Infections in dogs. Memorias Do Instituto Oswaldo Cruz, 1996, 91, 695-697.	1.6	59
119	Heading back into the perfect storm: increasing risks for disease emergence in Brazil?. Revista Da Sociedade Brasileira De Medicina Tropical, 0, 55, .	0.9	0
120	Influence of climatic variables on the number of cases of visceral leishmaniasis in an endemic urban area. Journal of Global Health Economics and Policy, 0, 2, .	1.0	0